Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 9/20 | 0.49 |
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.47 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721649 | 1.00 | CA12 (0.50) | CA12CA2CA9CA1MMP9 | |
| SCHEMBL3061047 | 0.92 | CTSS (0.49) | CTSSMMP8MMP3CTSLCTSB | |
| SCHEMBL3073642 | 0.86 | AKR1C3 (0.49) | CA12CA2MMP9MMP2CTSS | |
| SCHEMBL3061784 | 0.85 | CTSS (0.47) | CA12CA2CA9CA1MMP9 | |
| SCHEMBL695843 | 0.83 | CTSS (0.67) | CTSSCTSLCTSB | |
| SCHEMBL8507541 | 0.79 | CA12 (0.57) | CA12CA2CA9CA1MMP9 | |
| SCHEMBL3061404 | 0.77 | CTSS (0.54) | CTSSCTSLCTSB | |
| SCHEMBL6978548 | 0.77 | CA9 (0.56) | CA12CA2CA9CA1MMP9 | |
| SCHEMBL6978545 | 0.77 | CA9 (0.56) | CA12CA2CA9CA1MMP9 | |
| SCHEMBL696512 | 0.76 | CTSS (0.64) | CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | claimed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CA12 3773/4885CA2 3837/4885CA9 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.